NewAmsterdam Pharma Co N.V. filed 4 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-08-14. Between them they name 1 person. Each change below is quoted from the filing and linked to it.
Every change, newest first
Appointed: Robert W. Gunning
(the "Company") appointed Robert W. Gunning, age 55, as its principal accounting officer.
Reported
Also on the Separation Date, Mr. Kling entered into an Advisor Agreement (the "Advisor Agreement") with NewAmsterdam Pharma B.V., a wholly owned subsidiary of the Company, pursuant to which Mr. Kling will provide transition and advisory services related to the Company's PREVAIL clinical trial of obicetrapib and other clinical programs in exchange for a service fee of $50,000 per month plus reimbursable expenses incurred.
Reported
(the "Company") that he would resign as the Company's Chief Operating Officer, effective August 14, 2026, to be appointed as the chief executive officer of another clinical-stage biotech company.
Reported
(the "Company") and Louise Kooij agreed that her employment as the Company's Chief Accounting Officer would end effective August 31, 2026 (the "Separation Date").
Find people with the same kind of experience as the senior executive at NewAmsterdam Pharma Co N.V., with the record behind each one.
Find candidates like senior executive at NewAmsterdam Pharma Co N.V.New leaders review vendors and budgets in their first months. Get an alert the next time NewAmsterdam Pharma Co N.V. is in the news or changes leadership.
Get an alert when NewAmsterdam Pharma Co N.V. changes leadershipTools for this story
Each opens in a new tab, filled in for NewAmsterdam Pharma Co N.V.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.